Viewing Study NCT00183859


Ignite Creation Date: 2025-12-24 @ 2:35 PM
Ignite Modification Date: 2026-01-02 @ 7:32 AM
Study NCT ID: NCT00183859
Status: COMPLETED
Last Update Posted: 2014-05-22
First Post: 2005-09-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan
Sponsor: University of Southern California
Organization:

Study Overview

Official Title: Phase I Clinical and Pharmacokinetic Trial of Intra-Peritoneal Irinotecan
Status: COMPLETED
Status Verified Date: 2014-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a research study for patients that have an advanced cancer that is confined mostly to the abdominal cavity and have failed treatment with conventional therapy, or for which no standard treatment exists. The purpose of this study is to determine the dose of a chemotherapy drug (called irinotecan) that can be administered safely into the abdominal cavity. We also wish to identify the side effects of irinotecan when it is administered directly into the abdomen. In this study, we will also determine the levels of irinotecan in the blood and in the abdominal cavity.

Irinotecan is a chemotherapy drug that can decrease the size of several different tumors. It is approved by the FDA for the treatment of colon cancer. It appears that some other chemotherapy drugs are more effective and may have less side effects when they are administered directly into the abdomen.
Detailed Description: None

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: